Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer

Key Takeaways From the Phase 2 StudyAdding nivolumab to SOC radiation and hormone therapy was associated with a 2-year FFBR of 90.3% (95% CI, 74.3%-98.0%) in patients with high-volume grade group 5 prostate cancer.Definitive and probable nivolumab-related toxicity included grade 2 and grade 3 acute AEs in 6.3% of patients each, with no grade 4 or higher AEs reported.Ricketts Immunosuppression Score was identified as a potential predictive biomarker, with high scores independently associated with early pathological response and complete radiographic response, and low scores independently associated with increased risk of metastatic progression on multivariable analysis (HR, 9.256; P = .044).